Gout is the most common cause of inflammatory arthritis worldwide. In UK general practice, the overall prevalence has increased from 1.4% in 1999 to 2.49% in 2012 [1], despite the availability of effective and potentially curative urate-lowering drugs for >50 years and evidence-based British and European management guidelines for nearly a decade [2, 3]. NICE has accredited the process used by the BSR to produce its guidance for the management of gout. Accreditation is valid for 5 years from 10 June 2013. More information on accreditation can be viewed at www.nice.org.uk/accreditation. For full details on our accreditation visit: www.nice.org.uk/accreditation. Clinical manifestations of gout resulting from monosodium urate crystal deposition include tophi, chronic arthritis, urolithiasis and renal disease as well as recurrent acute arthritis, bursitis and cellulitis. Gouty arthritis and tophi are associated with chronic disability, impairment of health-related quality of life [4–7], increased use of healthcare resources and reduced productivity [8]. Gout is also frequently associated with co-morbidities such as obesity, dyslipidaemia, diabetes mellitus, chronic renal insufficiency, hypertension, cardiovascular disease, hypothyroidism, anaemia, psoriasis, chronic pulmonary diseases, depression and OA [1] as well as with an increase in all-cause mortality (adjusted hazard ratio 1.13, 95% CI: 1.08, 1.18) and urogenital malignancy [1, 9]. Sustained hyperuricaemia is the single most important risk factor for the development of gout. Hyperuricaemia occurs secondarily to reduced fractional clearance of uric acid in > 90% of patients with gout [10]. Age, male gender, menopausal status in females, impairment of renal function, hypertension and the co-morbidities that comprise the metabolic syndrome are all risk factors for incident gout associated with decreased excretion of uric acid, as are the use of diuretic and many anti-hypertensive drugs, ciclosporin, low-dose aspirin, alcohol consumption and lead exposure. Tophi and chronic arthritis [11], alcohol consumption [12] and recent use of diuretic drugs [13] are important risk factors for recurring flares. Genome-wide association studies have identified a number of genes coding for urate anion transporters expressed in the proximal renal tubular epithelium, but these account for <5% of the variation in serum urate [14]. Serum urate levels are influenced by dietary intake and synthesis as well as by renal excretion. Diets high in red meat or seafood, and increased consumption of beer, spirits and fructose- or sugar-sweetened soft drinks are established risk factors for developing gout [15–17]. Single gene disorders associated with urate overproduction, hyperuricaemia and accelerated purine synthesis de novo (such as glycogen storage diseases and Lesch–Nyhan syndrome) are very rare causes of primary gout. Diseases (such as lympho- and myeloproliferative disorders and severe exfoliative psoriasis) and drugs (such as cytotoxics, vitamin B12 and ethanol) associated with increased cellular turnover and destruction can lead to secondary hyperuricaemia and gout [18]. The identification of monosodium urate crystals in joint and tissue samples remains the gold standard for the diagnosis of gout. Although identification of urate deposits by dual-energy CT [19] and US [20] are being used increasingly as an aid to the diagnosis of gout in research and hospital practice, joint aspiration or imaging to confirm crystal presence is rarely undertaken in primary care settings where the majority of patients with gout are managed. For diagnosis in clinical practice, clinical scores, without imaging or synovial fluid analysis, have been proposed [21] that include consideration of the patient’s history and co-morbidities. The British Society for Rheumatology/British Health Professionals in Rheumatology (BSR/BHPR) guideline for the management of gout was published in 2007 [2]. There are four broad reasons why a revised and updated guideline is now required. First, new pharmaceutical have and the for the and of drugs has the prevalence and of gout have increased [1] despite the availability of effective and potentially curative research studies and have that of patients with gout in general urate-lowering and that many patients with gout being with in primary [1, and secondary care of serum uric acid levels to the in the or as has that the of information to patients with gout is and studies have to a of and to effective care are that that these can be and with of information and a of care on guideline published guidelines include the 2012 for the of Gout and the evidence-based for the diagnosis and management of gout by a of in the and guidelines include the US for and guidelines for of Gout and of Gout and the and and for the diagnosis and management of gout that from the for the management of gout published in guideline to revised and for the management of gout in the The guideline has been to to and and patients with gout in primary care and hospital The guideline also a for patients and for care for patients with gout in the Health for the diagnosis and of gout are in for the diagnosis of gout are in the recent for the diagnosis and management of gout and for the diagnosis of gout are in the process of being updated The guideline has been by a of general secondary care with in general clinical and patients and an with in evidence-based on of the and The guideline was and in by a at the of the BSR in and The without or pharmaceutical and of of all of the have been guideline has been and by the of The of the revised guideline and the clinical management that to be by at an of the guideline of the published guideline and of a clinical management to in clinical undertaken by to to from to the from to and the of and to in 2012 was updated in June at Rheumatology for studies and or where was and of hyperuricaemia to the management of gout. for the management of gout of the guideline to a of for the management of gout on research and clinical the published and the of the of and a of proposed for the management of acute to and and for the management of and chronic gout. for revised was of a by in with of with and and of and The for and at the of the BSR in on the most for was at a of the guideline and of the and the from of the The of in of was of at at without at at for or of a was for a for a studies that The of for by of the guideline development was on a by at the and by the The for management was on the of the guideline the research for and of and the of of the such as the and of and to the in as well as of in the of the the care for the management of gout serum uric urate-lowering patients to that be as as an occurs and that patients are of the of established an 90% The for patients to the of acute of gout as as is on common and of the of by patients with acute gout. of with an and with been in The to with urate-lowering drugs acute gout is on a of [2, and studies that that many patients are of the to be and in a and can be effective to The to is on and is that urate arthritis in is by and by have been of undertaken in patients with gout. The for is by a of a single in was to and In 95% CI: to on 10 was with use of without be used as to for acute or drugs are of co-morbidities. at or in of is the of are of on renal and co-morbidities. on or be a 95% published a that the management of acute gout. Although are used in general that is effective is that be by patient’s as well as by renal and co-morbidities. The of is by a single of have been with single There where is to be at high patients with acute gout of the of the and [2, frequently in patients with renal insufficiency, or a history of or such as have and but are cardiovascular and renal with chronic of is for patients with in with for Health and clinical guidelines For in at and that a low-dose by was and was associated with and as a of of the also that was quality for the of low-dose and for with high to be associated with ratio 95% CI: In the of for the and of proposed the BSR acute gout with in of are to The of by most frequently is in patients with and be reduced in patients with and in the also be used with and at in patients drugs that are of or ciclosporin, is also in patients in with renal as are of and use of and aspiration and of a are effective in acute gout and be the of in patients with acute and of or a single of an is an in patients are to or and in is is also for or of gout. in of use for the management of acute gout. and clinical that and can be very effective for acute arthritis of for acute gout that that of and In patients with acute gout where to is of can be is by in that the most used are with or or be in patients have to standard of acute gout by and are that have been to for the management of acute gout In an the by in and with is for use in by the European but in the by the and of its There are published for the use of an in patients with gout. an on in patients with gout or and a of its use in patients that be an effective and for acute arthritis in patients or and the and of are in a recent of and is by NICE for use in the of acute gout. in the UK be of the to for an these drugs are diuretic drugs are being used to hypertension an anti-hypertensive can be as as is and are used for a number of the management of hypertension, and causes of fluid have been to be associated with an increased risk of gout with a ratio of CI: a number of and a diuretic published in 2012 to the but as the number of studies was that was to the of all in patients with gout. recent the that the use of and was associated with the development of incident the use of was patients with gout be and information the the causes and of gout and to acute alcohol consumption and and the and use of to urate be and account co-morbidities and and to care be There is the of in gout. of has and with can In of the at was and in and studies that an of the causes and of that is a disease, and a of gout as being are important to in gout being in and to that are well studies have that such gout and its are associated with to and of disease or to are to gout frequently and in as well as disease, have been to be associated with health-related quality of life patients are frequently in details of the of dietary also have important to and that are In dietary to a in and be and be with all patients with and a in and and high in and be sugar-sweetened soft drinks be intake of drinks and be of and of and in the be and recent of studies identified a number of dietary factors that associated with gout. consumption of seafood, drinks and sugar-sweetened soft drinks and are all risk factors for incident gout. alcohol of of is also associated with an increased risk of recurrent gout consumption and high in dietary to be associated with a reduced risk of incident gout as well as a in risk of recurrent gout in but consumption has been and be to consumption of vitamin for the use of urate-lowering The urate-lowering of was in in with gout that consumption of and was associated with a risk of gout with intake was with the risk of gout was without ratio 95% CI: of the and of dietary in patients with gout for with and the for vitamin from was in with 95% CI: to but was in the number of acute or the for reduced the in patients with and also the of in the of of vitamin in patients with hyperuricaemia have gout in to have a in patients with gout is for use as and a that its as a urate-lowering used as an to standard with was with gout and a history of urolithiasis be to of and of the with be in recurrent are published of of urolithiasis in patients with gout and recurrent have been recent and of of management of recurrent urolithiasis in all There is from quality for risk with increased fluid intake 95% CI: and of risk with with 95% CI: risk factors and such as hypertension, diabetes mellitus, dyslipidaemia, and renal disease be for in all patients with at and 90% associated with gout are well The to these co-morbidities is also but at guidance that the of renal disease in patients with chronic disease and hyperuricaemia The of for co-morbidities is by a recent that has gout to be an risk factor for mortality from disease and renal disease The of be to patients the diagnosis is and are being information gout. be in the as to to The of and to the of gout be be the process of serum uric acid levels as can cause an increase in gout for full have been in guideline and are by from a of of the for is to the UK and has been in a in the in a in and in a in be and to all patients have a diagnosis of gout. be in patients with the recurring in chronic joint renal impairment a history of diuretic primary gout at a tophi, chronic arthritis, joint renal 95% the gout with has increased in the of patients with recurring tophi and chronic arthritis is by and the to with in all patients with gout is on and imaging that gout is a chronic crystal deposition disease at the of the For patients to have risk factors or co-morbidities with the of such consideration is The of the and of gout can but is the and as in is the in the of the disease, in that potentially can have a on quality of life is that hyperuricaemia is the of the that of at be the of gout is by from the UK Clinical that that the patients with gout for to with to gout patients with recurring acute by a in a healthcare that that of patients with gout a and that with in patients account the deposition of crystals and the by patients with Clinical and studies also that the risk of gout the serum urate is very high the as to to in also be influenced by the patient’s or as well as by consideration of the overall of and and the patient’s has that gout is an risk factor for mortality and for to disease and renal disease Gout is a risk factor for the development of renal and hyperuricaemia is an risk factor for renal impairment There is now from that in patients with and a published the that gout with renal of patients with gout and urolithiasis with is by studies the to in patients diuretic drugs is by studies and four studies that of arthritis in with of The to patients with primary gout at an with is on number of rare disorders associated with of purine glycogen storage diseases or associated with decreased fractional urate excretion can in the development of gout at an of patients by in that the at gout was and for of gout risk in and in in in the urate be important causes of gout in and in but from studies in the that factors have an important on serum urate levels and and factors are important risk factors for primary the of the rare single gene disorders of is has as is the is in Although a has that of an acute was associated with a increase in recurrent or inflammatory the that of a the was in the information to be in patients in are to the of of has The of is to and the at or a of to urate crystal and to The the the the of crystal years of tophi have and the remains of the of can be to the at or a of to crystal deposition and the of that be associated with a very to The of in the guideline remains the to crystal and recurrent that of crystal is associated with a is from The for to the of the is to crystal deposition and the of that be associated with a very is on a for such a and in the of studies that have a association levels and of disorders such as disease disease and an increased risk of incident disease in with with with is the to be at a and the increased in the has been In patients with renal be used and the be but urate levels be the for renal for the and of has been in a recent a of patients in with and of In in a of was effective but effective or these and studies of gout being in UK general have that many patients of to levels by the BSR or with in of or from the of and from the have that of is effective in to levels and well The of to be to the of in of the patients was and practice, the The that be the to is by studies Although well by the majority of is rarely associated with potentially with and or syndrome with and renal be used in the as the risk of with is increased patients of and for with has been of the high of in these with in on of a the use of full and the development of in patients with renal to to clearance studies that to in of in patients with gout and renal and a of a in of in patients to More studies by have that the of to the of renal the risk of and that increase in the the on in of to levels in most patients without increase in can be used as an for patients in is or renal impairment to the with a of increase to to 90% of to is a risk factor for a proposed of 2012 by by of and of have the of in and the risk of gout flares. with a of of and was effective in the to 95% CI: but the risk of gout 95% CI: There was in the of and the of patients the of and was is well and can be used in of or in patients and with to renal impairment There are on its use in patients with severe to are very but the risk of or with in patients with has to be with in patients with disease or is but are in in and to and the cardiovascular of and in patients with high cardiovascular risk and co-morbidities. Health studies have that is as a In the NICE have the use of is or the as a with is or can be used in patients are or The drugs are or in patients with or renal function, or in patients with to renal drugs the to be used for years and for is by a recent and of with with and with and a but have been of the drugs that are for use as in patients with gout in In an of patients well or was to be effective and and was with in to in are or to be used with in patients with urolithiasis or severe renal Clinical that and have in patients with or renal but has been to the is as as and are for the of patients with gout in the UK on a and patients these drugs be the care of a The use of was in rare of severe from with have but the risk of in patients the in is as in and be used as a primary but where for hypertension or dyslipidaemia, is be as have a also have a and used for hypertension, has been to have in patients with gout and the use of was associated with a reduced risk of incident gout 95% CI: in a UK from The Health The has been to be and to have a urate-lowering in gout patients being with and to have urate-lowering to gout patients with or in of that can be by vitamin in patients without gout and that in vitamin single in patients with gout that vitamin for reduced the in have a very in with is for to be used as for or the of that in is also to be a to standard with studies have been undertaken to vitamin is effective in the of recurrent gout can be used in with a in patients a serum urate with of of uric acid excretion and of in patients with gout by with and was nearly years studies by and have that the of in patients with chronic gout be accelerated with of by with and that gout patients that are primary of with increased uric acid also have of fractional urate clearance and to of a is reduced to levels with a More recent studies have also that with and was effective in recent single has effective of in a with gout and chronic renal with of a of and to of a single with was of a new uric acid have to be effective in of and in the to levels in with in patients with gout that have to in renal use for has been and and or be as acute resulting from or of and for to In patients a low-dose or with can be used as an are acute in patients has been the of recent There is from to the use of for for In a in patients with gout for the was reduced from to in patients In in patients at a of by in in of patients for with of with of gout from the of that for to with or the of with or to for with increase in There is research to the of identified a single for and recurrent acute gout was by and the the risk of was with or in patients with gout a consideration of the overall to risk in and in with co-morbidities and for or the of and cardiovascular risk be and with a is Although well of include and The use of is important is with as the in the UK the serum acid to a the of and the risk of a gout is There is research to the use of for have also been for use for but are for by the or and is that the of these use for in patients with gout in the UK In a of of and in patients with the number of was in the patients at all >50 but was of a and in the patients in and are very common in patients with gout. recent and of and studies that the overall prevalence of or in patients with gout was with in the and the prevalence of was with important in patients with and management of gout in patients with renal impairment has been the of recent and a guideline from the US For the management of acute the of be reduced in patients with but is in patients with severe renal impairment 10 be used in patients with renal impairment Although the of in with has been in clinical that can be effective and for acute gout in patients with severe renal impairment or in patients in and be for for is or are or a of to are or is for the use of and drugs in patients with renal impairment have been and for the use of urate-lowering with or in patients with gout and renal to be undertaken with as the of are increased in patients with renal impairment and can cause acute and renal in patients with with for renal function, is to be a low-dose on in patients with is that is for in or for in patients with renal but the be to in with an of and to with and 10 Although is that be in all patients with renal a recent and of studies of accelerated in patients with to severe renal impairment with low-dose 95% CI: with severe gout in hyperuricaemia be with standard or in be to a a can be effective in such patients by The is by in by with and for with and patients be with and to the risk of in to low-dose or for is be and the is as to be at increased risk for and is in patients with of the risk of and is in patients with has and in but has been by NICE or the of and a that is for the and of but for has also been used in patients with severe gout despite its in the UK be of the to for an these drugs be from patients with gout is very in and in and are are for acute can be used in the are to use in and the for the dietary are also The for are from studies of its use in are also of of can be in and is and have been was used in the of in without the prevalence of gout and the availability of effective and potentially curative for >50 its management remains with of patients with gout of information to patients has been identified as of the to effective management of gout. There is that to and of to levels can be with of information and a of care on guideline of information and of to levels clinical that secondary care of patients with on with a to primary care where is to be of with have a patients for be of recurrent and the for the for in the of Although are studies in the guideline these The guideline as the is and to be and effective in the majority of patients with gout. The of as a has been established and our guidance for its use with its NICE and The guideline include for or use of and the to use these drugs is to be rare and are to for these guideline important from the 2007 guideline [2]. The of and of information gout and its are in the updated guideline for the management of acute and for the of and risk factors and and for the use of urate-lowering is now that an or are drugs of for acute gout are and that the of be by renal function, co-morbidities and for the management of acute of with or can be used for acute where to is for the management of acute and be in patients have to standard for the management of acute The revised guideline that all patients with gout be for cardiovascular risk factors and such as hypertension, diabetes mellitus, dyslipidaemia, and renal disease at and for the of and risk is now that that the of be and to all patients with gout as of the and that patients are in the as to to and for the use of urate-lowering Although the revised guideline of with to a of to the of is now years of tophi have and the remains for the use of urate-lowering is now that in patients with renal impairment the of be to the The be and increased with the of is for the use of urate-lowering can be used as an for patients in is or renal impairment to the for the use of urate-lowering For patients with severe gout in hyperuricaemia be with standard or in with can be by with and for with is on the of the British Society for for and for clinical research can be at Rheumatology and in the was from in the or to the in from Health for Health and for from